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Abstract
Background: Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)
and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) are two rare
headache syndromes classified broadly as Trigeminal Autonomic Cephalalgias (TACs).
Methods: Here, 65 SUNCT (37 males) and 37 SUNA (18 males) patients were studied to describe their clinical
manifestations and responses to treatment.
Results: Pain was almost always unilateral and side-locked. There were three types of attack: Single stabs, stab groups,
and a saw-tooth pattern, with some patients experiencing a mixture of two types. As to cranial autonomic symptoms,
SUNA patients mainly had lacrimation (41%) and ptosis (40%). Most cases of the two syndromes had attack triggers, and
the most common triggers were touching, chewing, or eating for SUNCT, and chewing/eating and touching for SUNA.
More than half of each group had a personal or family history of migraine that resulted in more likely photophobia,
phonophobia and persistent pain between attacks. For short-term prevention, both syndromes were highly responsive to
intravenous lidocaine by infusion; for long-term prevention, lamotrigine and topiramate were effective for SUNCT, and
lamotrigine and gabapentin were efficacious in preventing SUNA attacks. A randomized placebo-controlled cross-over
trial of topiramate in SUNCT using an N-of-1 design demonstrated it to be an effective treatment in line with clinical
experience.
Conclusions: SUNCT and SUNA are rare primary headache disorders that are distinct and very often tractable to
medical therapy.
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Introduction
Short-lasting unilateral neuralgiform headache attacks
with conjunctival injection and tearing (SUNCT) is a
rare form of primary headache (1,2). It is clear in ter-
tiary headache practice that many patients do not
manifest both conjunctival injection and tearing (3).
The current terminology has evolved to respect the ini-
tial description and acronym, and acknowledge the
underlying physiological principle of co-existent cranial
autonomic activation (4). SUNCT syndrome was ini-
tially included in the second edition of the International
Headache Classiﬁcation and SUNA in the appendix
(5). In the latest version, ICHD-3 beta (6), SUNCT
and SUNA are included in the main body.
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At least two unresolved issues arise in these syn-
dromes. First, should they be collapsed under an
umbrella or left distinct? Given their rarity, substantial
series have not been available to explore the pheno-
types. Previously, we reported on 43 SUNCT and
nine SUNA patients (3); in the following decade, we
have seen more patients with these syndromes and
sought here to examine whether the syndromes are suf-
ﬁciently distinct to maintain their separation.
Moreover, we had noted in previous work that
migraine features in the phenotype appeared to be asso-
ciated with an underlying migrainous biology (3); we,
therefore, wished to test the question as to whether
having underlying migrainous biology inﬂuenced the
phenotypic expression of these syndromes with our
expanded cohort. Secondly, while there are treatment
guidelines (7), the body of evidence for the guidance is
minimal. We have been able to collect substantial treat-
ment response data, and uniquely have conducted a
randomized placebo-controlled trial of SUNCT to
test whether topiramate is an eﬀective treatment. We
therefore set out to provide experience as an evidence
base (8) for treatment recommendations.
Material and methods
Clinical material
All patients attended outpatient clinics at either the
National Hospital for Neurology and Neurosurgery
(NHNN), London, UK, between 2002 and 2007; the
Headache Center, University of California, San
Francisco (UCSF), San Francisco, CA, USA, from
2007 to 2013, or as outpatients at King’s College
Hospital, London, UK from 2013 to 2015. Patients
were diagnosed as having SUNCT or SUNA as deﬁned
by the International Classiﬁcation of Headache
Disorders, Second Edition (ICHD-2) (5) and were con-
sistent with proposed ICHD-3 beta criteria (6). Every
patient was seen by at least one of us (PJG). The cohort
represents those previously reported (3) whose clinical
data were re-reviewed, and additional cases. The study
was approved by the NHNN Institute of Neurology
Joint Research Ethics Committee (reference 00/N072),
by the UCSF Committee for Human Research, and is
presented as an audit of practice at King’s College
Hospital, London.
In every patient, detailed and standardised history-
taking was carried out, including the side, location, fre-
quency, duration, and character of their headaches,
types of attacks, accompanying symptoms, triggering
factors, personal and family histories, and their
responses to medicines or other treatments. The study
focuses on lateralization and type of attacks, cranial
autonomic symptoms, and treatment outcomes.
Clinical data analysis. All data were recorded using
Microsoft Excel. All descriptive calculations were per-
formed in Excel. Summary measures are reported for
the cohort as n’s with percentages. To test whether the
SUNCT and SUNA are diﬀerent based on phenotype as
a surrogate for biology, apart from the cranial auto-
nomic symptom distinction, we used a multinomial
logistic model, with a logit link function, and diagnosis
as the dependent variable (IBM SPSS Statistics v 22). To
test the relationship of background migrainous biology,
deﬁned as a personal or family history of migraine, to
the presence of a clinical phenotype, we used a binary
logistic model, with a logit link function, and the pres-
ence of migrainous biology as a binary dependent vari-
able. To test single phenotype questions, a chi squared
test was employed. For all analyses, signiﬁcance was set
as p< 0.05. The clinical eﬀect from preventives is rec-
orded as patients subjectively reported their eﬀects, and
as it was recorded in the documentation.
Clinical trial
Five male patients (aged 51–72, mean 59 years) with
SUNCT were recruited from the Outpatient department
at the National Hospital for Neurology and
Neurosurgery (NHNN), London, between 2003 and
2004 (Figure 1). They were initially diagnosed with
SUNCT using operational criteria later incorporated
into ICHD-2 (5). Inclusion criteria were: Diagnosis of
SUNCT; willingness to stop any current treatments; and
willingness to comply with a diary of attacks as they
occurred. Exclusion criteria were: Previous exposure
to topiramate; being pregnant or lactating; having a his-
tory of renal calculi; and any contraindications to the
use of topiramate according to the Summary of Product
Characteristics (Medicines and Healthcare products
Regulatory Agency- MHRA, UK). The subjects gave
their informed consent and were free to withdraw
from the study at any time. The study was conducted
before trial registration became commonplace (9).
Design. The design of the study was a randomised,
double-blind, placebo-controlled crossover trial of
topiramate. The treatments were topiramate tablets
and matching placebo, supplied by Janssen UK; and
labelled Treatment 1 and Treatment 2, to be taken in
the ﬁrst and second arm of the study, respectively. The
order of active treatment and placebo was randomised
by NHNN pharmacy, and each participant was
assigned a randomisation number. The code was held
by the pharmacy until study completion and database
locking.
Conduct. Patients were required to withdraw from
preventive medications prior to commencement
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of the study. After an initial washout drug-free period
of 10 days, treatment was started at topiramate 12.5mg
at night and increased every ﬁve days to a maximum of
50mg twice daily for 10 days, after which the dose was
reduced over the next 10 days, or the same regimen with
matched placebo. A 10-day washout drug-free period
followed, after which the patients commenced the
second arm of the study in the same paradigm. The
patients with episodic SUNCT started the 10-day wash-
out period at the start of their bout.
The patients were instructed to keep a diary for the
duration of the study, which documented the date,
time, severity, and duration of each attack.
Clinical trial data analysis. The primary endpoint was the
reduction of attack frequency, as measured by the mean
daily number of attacks during the 10 days at maximum
dose compared to the 10 drug free days pre-
treatment, comparing active and placebo treatment
arms. A secondary endpoint, ‘attack load’, was calcu-
lated as the number of minutes of pain per day for each
patient, to take account of longer attacks, such as saw-
tooth patterns (3). The results are presented on anN-of-1
basis. A positive result was declared for the endpoint in
each patient, if the outcome was reduced by 50% or
more compared to placebo. Given SUNCT attack fre-
quency can vary considerably from week to week,
we converted changes to percentages and calculated:
%therapeutic eﬀect¼ (topiramate change) minus
(placebo change).
Results
Clinical data
Subjects. One hundred and two cases were identiﬁed: 65
with SUNCT, and 37 with SUNA. There were 37 male
and 28 female SUNCT patients, and 18 male and
19 female SUNA patients. The mean age of onset
of SUNCT patients was 46 13 (mean SD; range:
13–75) years, and that of SUNA was 45 16 (range
15–92).
Laterality of attacks. Of all the SUNCT and SUNA
patients, 48 (47%) cases had only left-side attacks,
and 52 (51%) cases had attacks exclusively on the
Assessed for eligibility (n = 12) 
Excluded  (n = 7) 
♦ Not meeting inclusion criteria (n = 0) 
♦ Declined to participate (n = 7) 
♦ Other reasons (n = 0) 
Analysed  (n = 5) 
♦ Excluded from analysis (n = 0)
Lost to follow-up (give reasons) (n = 0) 
Discontinued intervention (n = 0) 
Allocated to placebo (n = 5) 
♦ Received allocated intervention (n = 5)
♦ Did not receive allocated intervention (n = 0)
Lost to follow-up (give reasons) (n = 0) 
Discontinued intervention  (n = 0) 
Allocated to topiramate (n = 5) 
♦ Received allocated intervention (n = 5)
♦ Did not receive allocated intervention (n = 0)
Analysed  (n = 5) 
♦ Excluded from analysis (n = 0)
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Analysis 
Follow-Up
Randomized (n = 5) 
Enrollment 
Figure 1. CONSORT flow diagram.
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right side; 12 (12%) cases had unilateral attacks with
side variance; one case had a unilateral attack with
nearly equal possibility of left or right side; only one
case had experienced bilateral attacks.
Cranial autonomic symptoms. By deﬁnition, every SUNCT
patient had attacks with both an ipsilateral conjunctival
injection and lacrimation, while less than half of SUNA
patients had either. SUNCT is generally more feature-
full in terms of cranial autonomic symptoms than is
SUNA. SUNA is dominated by lacrimation, nasal
symptoms, and ptosis (Table 1).
Comparing the phenotypes
Triggering. Among SUNCT patients, one patient had
only triggered attacks, with no spontaneous ones.
Eight (12%) SUNCT patients had only spontaneous
attacks with no triggered ones. All the other patients
had both spontaneous and triggered attacks. In SUNA
patients, 10 (27%) patients had only spontaneous
attacks with no triggers, and the remainder had more
triggered attacks than spontaneous ones. Of all
SUNCT patients, 56 (86%) cases had pain attacks
with a cutaneous trigger. The most common triggers
included touch (39 cases, 60%), chewing or eating (35
cases, 54%), the wind (24 cases, 37%) and brushing the
teeth (23 cases, 35%). Among SUNA patients, 32
(86%) cases had pain with triggers. The most frequent
triggers of SUNA cases were chewing or eating (12
cases) and touch (10 cases).
Refractory period. Of SUNCT cases for whom we had
data, 1/52 had a refractory period to cutaneous trigger-
ing. Of SUNA cases, 4/32 had a refractory period after
cutaneous triggering.
Types of attacks. Attacks of SUNCT and SUNA take
one or more of three forms: Single stabs, a group of
stabs, or a saw-tooth pattern of stabs. In this cohort,
SUNCT patients had more single stabs, while SUNA
had more groups of stabs (2¼ 23.4, p< 0.0001). The
saw-tooth pattern was comparable in both conditions
(Table 2).
Migrainous background
Both SUNCT and SUNA patients had a background
migrainous biology in 57 % of cases for which we had
data. In a model examining the pain features, a
migrainous background was strongly associated with
background pain between attacks (Wald 2¼ 6.5,
p¼ 0.01) and worsening of pain during the attack
(Wald 2¼ 8.2, p¼ 0.004). In a model examining the
canonical migraine features, the presence of nausea
was not associated with migrainous biology (Wald
2¼ 1.04, p¼ 0.307), whereas the presence of either
photophobia or phonophobia was associated (Wald
2¼ 6.8, p¼ 0.009). Worsening of background pain
with movement was seen in 26% (n¼ 55) of SUNCT
cases and in 46% (n¼ 28) of SUNA cases. Nausea was
seen in 27% (n¼ 64) of SUNCT cases and 29% (n¼ 35)
of SUNA cases. Similarly, for photophobia or phono-
phobia, 61% (n¼ 64) of SUNCT and 58% (n¼ 36) of
SUNA cases had one, or both, symptoms.
Treatment effects
Short-term prevention. Sumatriptan was used in 14
SUNCT and nine SUNA patients, and the attacks les-
sened in only one of each. High-ﬂow oxygen was tried,
but neither SUNCT nor SUNA cases were responsive.
Placebo-controlled indomethacin injections (10) had no
eﬀect on either SUNCT or SUNA. Intravenous lido-
caine had a very good eﬀect in reducing attacks of
SUNCT (100%) and SUNA (88%), when it could be
Table 1. Cranial autonomic features.
Feature
SUNCT
n (%)
SUNA
n (%)
Conjunctival injection 65 (100) 7 (24)
Lacrimation 65 (100) 14 (48)
Nasal: Blocking or rhinorrhea 44 (67) 12 (36)
Aural fullness 12 (50) 5 (17)
Periorbital oedema 25 (41) 8 (29)
Forehead/facial:
Sweating 4 (7) 1 (3)
Flushing 11 (18) 5 (17)
Sympathetic:
Ptosis 31 (51) 11 (38)
Miosis 1 (2) 0
Table 2. Pattern of attacks.
SUNCT
n (%)
SUNA
n (%)
Single stabs 41 (64) 8 (37)*
Groups of stabs 23 (36) 23 (62)*
Saw-tooth pattern 22 (34) 9 (24)
Single stabsþ groups of stabs 10 (18) 2 (9)
Single stabsþ saw-tooth pattern 5 (9) 1 (5)
Groups of stabsþ saw-tooth pattern 1 (2) 1 (5)
Single stabsþ groups of stabsþ
saw-tooth pattern
3 (5) 0
*p< 0.0001
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tolerated. Dihydroergotamine (11) and corticosteroids
seem generally unhelpful in both SUNCT and SUNA.
Greater occipital nerve (GON) injections (12) were
beneﬁcial in 50% (6 of 12 cases) of SUNCT patients,
but had no reliable eﬀect in SUNA cases (Table 3).
Long-term prevention. Lamotrigine had a good eﬀect in
reducing the frequency or severity of the attacks in
62% of SUNCT and 31% of SUNA patients at doses
of about 100 to 600mg/day (Table 4).
Topiramate had a good eﬀect in 48% of SUNCT
patients at doses of 50–500mg/day. However, no
SUNA case had a good or better response to
topiramate.
Gabapentin was used in 18 SUNA patients at a dose
of 1800–2400mg/day; seven cases had good to moder-
ate improvement (39%). In addition, gabapentin was
also beneﬁcial in 11 of 29 SUNCT cases.
Carbamazepine also had a good to moderate
eﬀect in 36% of SUNCT patients at doses of
100–1200mg/day. Carbamazepine was eﬀective in
20% of SUNA cases.
Brain imaging
There were 55 SUNCT (85%) and 33 SUNA (89%)
patients with brain imaging, which were almost all
magnetic resonance (MR). No abnormal ﬁndings on
brain images were identiﬁed in 42 SUNCT (76%) and
31 SUNA (94%) cases, and apart from pituitary
changes, none were SUNCT or SUNA related.
There were four SUNCT patients with pituitary
lesions. Two of them had macroadenomas, which
resolved after treatment of the tumors. The other
two had microadenomas, and one of them became
pain-free for eight months after resection of the
tumor. Vascular loops were found in the brain MR
of ﬁve SUNCT (10%) and two SUNA (8%) patients.
Among them, three SUNCT and two SUNA cases
had vascular loops compressing the trigeminal
nerves, one was ipsilateral to the pain, one had bilat-
eral loops but unilateral pain only, and one had a
vessel loop at one side but had bilateral pain. One
SUNCT and two SUNA cases received microvascular
decompression: One SUNA case was pain-free for
only three months after the surgery, and the operation
had no eﬀect in improving the attacks of the SUNCT
and the other SUNA cases.
Clinical trial
All ﬁve patients completed the trial (Figure; Table 5).
Patient #1 had a good eﬀect whilst on placebo, with
complete cessation of his attacks. On topiramate, there
was an increase of both attack frequency and attack
load. He was classiﬁed as a topiramate failure;
indeed, it appeared to worsen his problem.
Patient #2 had a reduced frequency of attacks by
71% compared to placebo; he was classiﬁed a success.
He also had a substantial reduction in attack load com-
pared to the placebo period.
Patient #3 had complete cessation of his attacks on
topiramate, and a milder 15% reduction on placebo.
He was classiﬁed as a success. He did not provide
attack length data.
Patient #4 had a 5% diﬀerence between placebo and
topiramate arms in terms of frequency, and was
Table 3. Effect of acute treatments of TACs on SUNCT and
SUNA.
SUNCT SUNA
Total
n
Effective
n
Total
n
Effective
n
Sumatriptan 6mg sc 14 1 9 1
Oxygen 12–15 L/min 100% 14 0 7 0
Indomethacin 100mg imi* 13 0 6 0
Lidocaine (iv) 15 15 9 8
Dihydroergotamine,
iv over 5 days**
5 0 5 0
Corticosteroids – oral
high dose
20 2 6 0
Greater occipital nerve
injection***
12 6 4 3
*Placebo controlled (10); **over five days (11); ***with lidocaine and
depomethylprednisolone ipsilateral to pain (12).
Table 4. Effectiveness* of preventive.
SUNCT SUNA
Total
n
Effectiveness
n (%)
Total
n
Effectiveness
n (%)
Lamotrigine 29 18 (62) 16 5 (31)
Topiramate 27 13 (48) 9 1
Gabapentin 29 11 (38) 18 7 (39)
Carbamazepine 43 16 (36) 20 4 (20)
Oxcarbazepine 7 1 (14) 6 0
Pregabalin 7 1 (14) 16 1
Verapamil 16 2 (13) 5 0
Valproate 13 0 4 0
Beta-blocker 7 0 4 0
Tricylic 36 3 17 3
*Effectiveness: Reported to be useful in reducing frequency or severity of
attacks by the patient.
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classiﬁed as a topiramate failure. On the secondary
measure, there was a greater than 200% reduction in
attack load.
Patient #5 had an 8% reduction in frequency on the
placebo arm when compared to the topiramate arm.
He was classiﬁed as a failure. On the secondary end-
point of attack load, he worsened by 115 %.
Overall, on the primary endpoint, two patients had
improvement, two patients had no change and one
worsened.
Clinical trial – adverse events. One patient (#4) reported
peripheral paraesthesiae on topiramate. One patient
(#5) reported peripheral paraesthesiae on both treat-
ments and also had dull headache attacks whilst on
both treatments, which were not related to his
SUNCT or migraine, and not recorded as such.
He had one episode of diplopia lasting an hour on pla-
cebo, and reported indigestion whilst on topiramate.
Discussion
In this substantial cohort of patients with SUNCT and
SUNA, we have been able to explore similarities and
diﬀerences between the conditions, and explore treat-
ment outcomes. The data suggest suﬃcient diﬀerences
in core phenotypes to maintain the current classiﬁca-
tion. Cranial autonomic symptoms are distributed
diﬀerently, even allowing for the deﬁnitional constraint
in SUNCT. Attack pain features show SUNCT being
more likely to have single stabs and SUNA more likely
to have groups of stabs. In terms of preventive treat-
ments, SUNA is generally less responsive, being most
likely to be improved by gabapentin or lamotrigine,
while SUNCT is more likely to be improved by
lamotrigine and topiramate. Our small randomised pla-
cebo-controlled trial of topiramate in SUNCT supports
the clinical data and, since SUNA seems much less
likely to respond, provides another hint that the condi-
tions have some diﬀerence. While the data certainly do
not settle the issue of whether SUNCT is on a con-
tinuum with SUNA, they do suggest it is reasonable
from both a clinical and research perspective to main-
tain the distinction until more data can be collected.
The outcome of treatments is instructive as to the
biology of SUNCT/SUNA. The conditions respond
very well, almost invariably, to intravenous lidocaine,
if it is tolerated. There is no eﬀect of oxygen, which
although open label, was administered in a dose eﬀect-
ive for cluster headache (13). Similarly, while cluster
headache is very likely to respond to sumatriptan by
injection (14), one only in each group responded here.
Again corticosteroids, which can certainly be helpful in
the short term in many patients with cluster headache
(15), were not useful in most patients with SUNCT or
SUNA. In contrast to paroxysmal hemicrania, where
an indomethacin eﬀect is diagnostic (16), no such eﬀect
is seen in SUNCT or SUNA. One outcome shared with
all the TACs, indeed with migraine (12), is a useful
eﬀect of greater occipital nerve injection (GONi) with
Table 5. Clinical trial: Demographics and outcomes.
Patient
#1 #2 #3 #4 #5
Age (years) 72 54 60 59 51
Duration of SUNCT attacks 120–1800 s 1 s stabs,
3600 s groups
5 s 1 s stabs,
300 s groups
60 s
Daily frequency of attacks pre-placebo 7 13 140 13 10
% change in frequency on placebo 100 þ52 15 þ22 10
Daily frequency of attacks pre-topiramate 2 23 138 10 6
% effect – frequency topiramate þ2063 19 100 þ27 18
Primary endpoint
%gain
Topiramate  placebo
þ2163 71 85 þ5 8
Daily attack load (minutes) pre-placebo 3 5 NA 93 11
% change in attack load on placebo 100 þ178 NA þ192 þ45
Daily attack load pre-topiramate 57 33 NA 197 3
% change in attack load on topiramate þ920 71 NA 17 þ160
Secondary endpoint
%effect
Topiramate  placebo
þ1020 249 NA 209 þ115
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local anesthetic and corticosteroid. The distinction
between that eﬀect and the lack of eﬀect of high dose
corticosteroids alone suggests the GONi has more than
an eﬀect of corticosteroid dose.
An interesting issue that has arisen in the literature is
the relationship between SUNCT/SUNA and trigem-
inal neuralgia (17). The distribution of pain seems
clearly diﬀerent: SUNCT/SUNA much more often
involves the ophthalmic division of the trigeminal
nerve, in more than two-thirds of cases (3), while tri-
geminal neuralgia only involves this division in 4% of
cases (18). Cranial autonomic symptoms are the rule in
SUNCT/SUNA, with more than 99% of SUNCT/
SUNA we have reviewed having one or more, and all
SUNCT patients having at least two, while, depending
on what cases are accepted, the rate is considerably less
in trigeminal neuralgia (18). Less than 5% of SUNCT/
SUNA patients presented in our cohort had a refrac-
tory period to re-triggering, while almost all trigeminal
neuralgia patients have a refractory period. The pain of
trigeminal neuralgia is classically described as short
electric-shock like pains, whereas up to one-third of
our SUNCT/SUNA cohort had the saw-tooth pattern,
which is invariably longer than a less than one second
stab. Interestingly, both conditions have background
pain in about half of patients (19); this would ﬁt well
to a common basis for that pain, i.e. associated
migrainous biology rather than a common mechanism
for trigeminal neuralgia and SUNCT/SUNA. The
treatment recommendations for SUNCT/SUNA, and
our data, diﬀer considerably to those for trigeminal
neuralgia. Carbamazepine and oxcarbazepine are
preferred treatments for trigeminal neuralgia, with
lamotrigine and gabapentin having insuﬃcient evidence
for recommendation (20). In contrast, lamotrigine
emerges as the most useful treatment for SUNCT,
next topiramate, which now has randomised placebo-
controlled trial data, while gabapentin emerges as the
most useful treatment of SUNA. Remarkably, topira-
mate is not listed in the top tier treatments of trigeminal
neuralgia (20). The ﬁnding of an abnormal vascular
loop is common in classical trigeminal neuralgia
(21,22). We report these loops in 10% of cases.
An important limitation of our data is that they were
not collected with this question in mind, scanners used
were not uniform, and we only had clinically noted
reporting. We remain impressed by the indiﬀerent
eﬀects of surgery beyond what would be expected
after manipulation in this region and anaesthetic.
Lastly, functional imaging studies have established
changes in the posterior hypothalamic region in
SUNCT (23,24), whereas no such changes have been
reported in trigeminal neuralgia. Taken together, the
evidence to diﬀerentiate between SUNCT/SUNA and
trigeminal neuralgia is strong. One possible issue
is under-diagnosis of SUNA in what is, in our experi-
ence, often called atypical trigeminal neuralgia (25).
This issue certainly deserves further attention.
A family history in SUNCT is reported in only one
cohort (26). Regarding other trigeminal autonomic
cephalalgias, there are reports of familial cluster head-
ache (27–30), familial paroxysmal hemicrania (31) and
familial hemicrania continua (32), as well as twins with
cluster headache (33–35). Whether the rarity of familial
cases reﬂects a non-genetic basis to the condition or
simply the rarity of the problem remains an important
unresolved issue.
The majority of SUNCT and SUNA cases were
idiopathic in previous reports. SUNCT syndrome was
delineated in patients with microprolactinomas (36)
and macroprolactinomas (37,38), with attacks appear-
ing on the same side as the tumors. A further ﬁve
SUNCT cases were reported with pituitary adenomas,
all with attacks ipsilateral to the side of the tumor (39);
among the ﬁve patients, two of them did not improve
after surgical removal of the tumor, one case was pain-
free after surgery, one case was pain-free for 1 year then
the pain relapsed with tumor recurrence, and one
patient had a major reduction in headaches. In our
cohort, there were four SUNCT and no SUNA cases
with pituitary lesions (two macroadenomas and two
microadenomas). When one considers TAC presenta-
tions and pituitary tumours (40) in the context of popu-
lation-based pituitary tumour presentations (41), and
the subsequent concordant course of the disorders,
there does seem to be a relationship between TACs
and acromegaly/prolactinoma not accounted for by
chance.
In the literature, SUNCT patients were reported to
be responsive to topiramate at doses of between 75
and 300mg/day (42,43). The data from our reported
cohort suggest about half of SUNCT patients ﬁnd
topiramate useful whereas few patients with SUNA
ﬁnd it useful. The open label SUNCT data are now
supported by the placebo-controlled data that we
report. SUNCT is rare, and doing large controlled
trials in SUNCT prevention is challenging. The
N-of-1 crossover approach is appropriate for this
patient group. The ﬁnding that two of the ﬁve patients
clearly beneﬁtted on the primary endpoint and one on
an important secondary endpoint of reducing time
spent in pain, supports the open label experience
and oﬀers a clear mandate to continue to oﬀer topir-
amate to SUNCT patients.
The issue of inter-paroxysmal pain in SUNCT/
SUNA, and more broadly in trigeminal autonomic
cephalalgias, is an important pathophysiological issue.
It can confuse clinicians and certainly can be an import-
ant part of the disability of these conditions. In these
patients, a little more than half had some identiﬁed
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migrainous biology, which we deﬁned operationally
as a personal or family history of migraine. While this
seems considerable, if one reviews the cumulative life-
time migraine incidence for episodic migraine, it is 43%
in females (44). If one adds in patients with probable
migraine and chronic migraine, it could be easily seen
that the gene pool for migraine in females is about
50%. It could be argued that the rates we see here are
a combination of that gene pool and the diagnostic bias
of seeing a physician. Interestingly, inter-paroxysmal
background pain was strongly associated with migrain-
ous biology, as was a worsening of pain with move-
ment, and the presence of photophobia and
phonophobia. It may be argued that SUNCT and
SUNA facilitate the expression of migrainousness,
which expresses itself in these other features.
Interestingly, nausea did not seem to be associated,
which may be because it is relatively less common or
because the SUNCT/SUNA eﬀect on migraine path-
ways is not universal.
In summary, a very substantial cohort of patients
with SUNCT and SUNA is presented. Based on the
phenotypic presentation of the pain features and the
distribution of cranial autonomic symptoms, the two
seem diﬀerent. This is supported by diﬀerences in
response to preventive therapies, particularly topira-
mate, for which we supply data from a randomised
placebo-controlled trial. An analysis of the clinical,
therapeutic, and pathophysiological ﬁndings in
SUNCT/SUNA supports their diﬀerentiation from
classical trigeminal neuralgia. The ﬁndings of associ-
ations between background migrainous biology and
features such as inter-paroxysmal pain and aggravation
of pain with movement, suggest SUNCT and SUNA
can trigger the expression of an underlying migrainous
process that colours the clinical presentation. SUNCT
and SUNA seem well placed as trigeminal autonomic
cephalalgias (TACs), and our clinical data oﬀer both
directions for new work and consolidate what is known
about these rare and highly disabling conditions.
Clinical implications
. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)
and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) are
two rare headache syndromes classiﬁed broadly as trigeminal autonomic cephalalgias (TACs).
. Regarding cranial autonomic features, SUNA patients were most likely to have lacrimation and ptosis.
. Patients with SUNCT and SUNA who had had a personal or family history of migraine were more likely to
have photophobia, phonophobia and persistent pain between attacks.
. A randomized placebo-controlled cross-over trial of topiramate in SUNCT using an N-of-1 design supports
oﬀering this therapy to patients with SUNCT.
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